Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 6/20 | 0.44 |
| ▸ | HTR1A | P08908 | 3/20 | 0.44 |
| ▸ | RBP4 | P02753 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | HTR5A | P47898 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 2/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9283305 | 0.84 | OPRD1 (0.50) | HTR6HTR1AHTR2AHTR7BACE1 | |
| SCHEMBL5666316 | 0.82 | TSHR (0.48) | HTR1AHTR2AADRB1 | |
| SCHEMBL5564533 | 0.81 | BACE1 (0.44) | HTR6HTR1AHTR2AHTR7HTR5A | |
| SCHEMBL8623037 | 0.81 | BACE1 (0.51) | HTR6HTR1AHTR2AHTR7HTR5A | |
| SCHEMBL8092711 | 0.81 | ITGB3 (0.43) | HTR6HTR1AHTR2AHTR7HTR5A | |
| SCHEMBL5563018 | 0.80 | MAPK1 (0.51) | HTR6ADRB1KMT2A | |
| SCHEMBL7841604 | 0.80 | ALDH1A1 (0.54) | HTR6HTR1AHTR2AHTR7HTR5A | |
| SCHEMBL1742847 | 0.80 | ADRB1 (0.51) | HTR6HTR1AHTR2AHTR7HTR5A | |
| SCHEMBL5563304 | 0.79 | ALDH1A1 (0.46) | BACE1ADRB1 | |
| SCHEMBL16230836 | 0.79 | PRMT5 (0.44) | HTR6HTR1AHTR2AHTR7HTR5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140148464-A1 | SALT FORMS OF FATTY ACIDS FOR THE TREATMENT OF DRY EYE | THETIS PHARMACEUTICALS LLC (US) | 2014-05-29 | — | — | US | disclosed |
| WO-2014008379-A2 | DIAMINE AND MEGLUMINE SALT FORMS OF FATTY ACIDS | THETIS PHARMACEUTICALS LLC (US) | 2014-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148464-A1 | SALT FORMS OF FATTY ACIDS FOR THE TREATMENT OF DRY EYE | SLC27A1, SLC27A2, FFAR2 | HTR6 1740/4885HTR1A 2713/4885RBP4 185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.